RxDoctor Payments Data

Richard Hightower, MD

Family Medicine · Pooler, GANPI 1487652285

Payments from drug & device makers

$13,708in general payments, 2019–2025

Across 894 payments — averaging $15.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$2K
  • Pfizer$1K
  • AstraZeneca$1K
  • AbbVie$1K
  • Lilly USA, LLC$1K
  • Amgen$505
  • plus $7K from 54 others

What the payments were for

  • Food & beverage$13,55999%
  • Education$901%
  • Gifts$590%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novo Nordisk140$1,689
Pfizer104$1,489
AstraZeneca(2 entities)80$1,262
AbbVie(2 entities)81$1,194
Lilly USA, LLC75$1,000
Amgen(2 entities)34$505
Astellas Pharma US Inc23$496
Boehringer Ingelheim31$493
Novartis26$417
GSK29$414
Sanofi-aventis U.S. LLC22$338
Johnson & Johnson21$318
Otsuka America Pharmaceutical, Inc.14$296
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC18$292
Merck20$285
Esperion Therapeutics, Inc.13$203
Axsome Therapeutics, Inc.9$201
Takeda Pharmaceuticals U.S.A., Inc.11$200
Mannkind Corporation6$195
Biohaven Pharmaceutical Holding Company Ltd.8$182
Abbott9$175
Bayer10$173
Corium, LLC7$160
Antares Pharma, Inc.8$157
Amarin Pharma, Inc.8$138
Exact Sciences9$134
Idorsia Pharmaceuticals US Inc7$122
Dexcom, Inc.7$106
Kowa Pharmaceuticals America, Inc.8$100
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)5$84
Boston Scientific4$83
Nestle Healthcare Nutrition Inc.3$66
VBI Vaccine (delaware) Inc.4$65
Harmony Biosciences LLC2$55
Biohaven Pharmaceuticals, Inc.3$54
Ironshore Pharmaceuticals Inc.3$53
Phathom Pharmaceuticals, Inc.4$51
Teva Pharmaceuticals USA, Inc.3$43
Xeris Pharmaceuticals, Inc.2$39
Genentech USA, Inc.2$39
Vistapharm, Inc.2$30
Halozyme Inc1$23
Grifols USA, LLC1$23
Biogen1$22
Sanofi Pasteur Inc.1$19
Sumitomo Pharma America, Inc.1$18
Eisai Inc.1$18
Ardelyx, Inc.1$17
IBSA Pharma Inc.1$17
Bausch Health US, LLC1$17
Shield Therapeutics Inc1$16
Gilead1$16
Lundbeck LLC1$16
Nalpropion Pharmaceuticals LLC1$15
Metuchen Pharmaceuticals1$13
Arbor Pharmaceuticals, Inc.1$13
Nevro Corp.1$13
Aytu Biopharma, Inc.1$13
Jazz Pharmaceuticals Inc.1$12
E.r. Squibb & Sons, L.L.C.1$11

How this compares

$13,708 in reported general payments places this provider in the 95th percentile of 3,111 family medicine providers in Georgia.

See all family medicine providers in Georgia

Medicare billing

Part B allowed, 2024
$320,545
Medicare patients
524
Services billed
13,608

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RybelsusSemaglutide60$91,620
TrulicityDulaglutide70$89,729
EliquisApixaban77$86,369
OzempicSemaglutide47$73,283
JanuviaSitagliptin Phosphate60$70,378
XareltoRivaroxaban56$54,835
FarxigaDapagliflozin Propanediol47$49,455
JardianceEmpagliflozin58$48,193
Trelegy ElliptaFluticasone/Umeclidin/Vilanter44$38,271
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog18$34,954
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog38$25,146
MyrbetriqMirabegron27$21,079
EntrestoSacubitril/Valsartan13$14,936
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog24$11,918
Novolog FlexpenInsulin Aspart40$10,972

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskRybelsus, Ozempic$1,689$164,903107 claims
Lilly USA, LLCTrulicity$1,000$89,72970 claims
PfizerEliquis$1,489$86,36977 claims
MerckJanuvia$285$70,37860 claims
Johnson & JohnsonXarelto$318$54,83556 claims
AstraZenecaFarxiga$1,262$49,45547 claims
Boehringer IngelheimJardiance$493$48,19358 claims
GSKTrelegy Ellipta$414$38,27144 claims
Astellas Pharma US IncMyrbetriq$496$21,07927 claims
NovartisEntresto$417$14,93613 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,111 family medicine providers in Georgia.

Other family medicine in Pooler

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →